Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Inclusion Criteria: * males and females, 18 or older * chronic phase Ph+ or BCR-ABL positive CML * current complete hematologic response to imatinib * lack of major molecular response * on imatinib for at least one year * on the same imatinib dose for at least 6 months * adequate hepatic and renal function Exclusion Criteria: * History of accelerated or blast phase CML * Serious uncontrolled medical disorder or active infection * Significant cardiovascular disease or bleeding disorder * Concurrent use of medications at risk of causing Torsades de Pointe